论文部分内容阅读
将小鼠MC3T3-E1成骨样细胞传代培养后分为8组:正常对照组(NC);成骨诱导对照组(OI);罗格列酮5μmol/L组(R5);罗格列酮10μmol/L组(R10);甘精胰岛素10-7mol/L组(G10-7);甘精胰岛素10-8mol/L组(G10-8);罗格列酮5μmol/L+甘精胰岛素10-8mol/L组(R5+G10-8)及罗格列酮10μmol/L+甘精胰岛素10-7mol/L组(R10+G10-7)。分别测定MC3T3-E1细胞碱性磷酸酶活性及增殖能力。结果与正常对照组比较,R10组能抑制前成骨细胞的增殖。而R10+Q108组与R10组相比,能对抗罗格列酮的抑制细胞增殖的作用,使细胞数目增加,P<0.05。与正常对照组比较,OI组能刺激前成骨细胞分泌碱性磷酸酶,与正常对照组相比,2个浓度的罗格列酮与甘精胰岛素均减少了ALP的活性。而且罗格列酮组ALP活性的下降比甘精胰岛素组明显。高浓度联合用药组ALP活性也明显低于对照组,但是联合用药组ALP活性值比罗格列酮单药组高,R5+G10-8组ALP活性值和R5组相比,(P<0.05)。结论:罗格列酮能抑制前成骨细胞增殖,甘精胰岛素能对抗罗格列酮抑制细胞增殖的作用;罗格列酮与甘精胰岛素均可抑制前成骨细胞分化,甘精胰岛素与罗格列酮联用,能对抗罗格列酮抑制前成骨细胞分化的作用。
The MC3T3-E1 osteoblast-like cells were subcultured and divided into 8 groups: normal control group (NC), osteogenic induction control group (OI), rosiglitazone 5μmol / L group (R5), rosiglitazone 10μmol / L group (R10); glargine 10-7mol / L group (G10-7); glargine 10-8mol / L group (G10-8); rosiglitazone 5μmol / L + insulin glargine 10- 8mol / L group (R5 + G10-8) and rosiglitazone 10μmol / L + insulin glargine 10-7mol / L group (R10 + G10-7). The alkaline phosphatase activity and proliferation ability of MC3T3-E1 cells were measured respectively. Results Compared with the normal control group, R10 group could inhibit the proliferation of pre-osteoblasts. Compared with R10 group, R10 + Q108 group could antagonize the effect of rosiglitazone on cell proliferation and increase the number of cells (P <0.05). Compared with the normal control group, OI group can stimulate the secretion of alkaline phosphatase in pre-osteoblasts. Compared with the normal control group, rosiglitazone and insulin glargine at two concentrations reduced ALP activity. Moreover, the decrease of ALP activity in rosiglitazone group was more significant than insulin glargine group. ALP activity in combination group was significantly lower than that in control group, but ALP activity in combination group was higher than that in rosiglitazone alone group, ALP activity in R5 + G10-8 group was significantly higher than that in R5 group (P <0.05 ). CONCLUSION: Rosiglitazone can inhibit the proliferation of pre-osteoblasts, and insulin glargine can antagonize the effect of rosiglitazone on cell proliferation. Both rosiglitazone and insulin glargine can inhibit the differentiation of pre-osteoblasts, Rosiglitazone can antagonize the effect of rosiglitazone on pre-osteoblast differentiation.